Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
By René S. Kahn, W. Fleischhacker, H. Boter, M. Davidson, Y. Vergouwe, I. Keet, M. Gheorghe, J. Rybakowski, S. Galderisi, J. Libiger and 9 more. The Lancet, 2008
1,099 citations recorded by the source corpus.
Subfields: Clinical Psychology, Molecular Biology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/fe9ddf622f645f90fee48edc234bb986695e9069
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Clinical Psychology
In Psychiatry and Mental health
Citations in the corpus
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, background): “In particular, haloperidol is a potent antipsychotic drug for the treatment of psychotic symptoms in acute schizophrenia and its effi cacy and safety has been confi rmed in many studies and metaanalyses over the years (Joy et al. 2006a; Kahn et al. 2008; Leucht et al. 2008, 2009b).”
- Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders (2016, neutral): “Second-generation antipsychotic agents (SGAs) are recommended in preference to first-generation antipsychotic agents (FGAs) due to their better tolerability and extrapyramidal side-effect profile (Kahn et al., 2008) (see ‘Antipsychotic medication’ in ‘Section 3.”
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) (2009, background): “At present, it is uncertain whether these short-term changes will translate into clinically relevant differences in the long term [41,60,73,93, 122,134,139].”
- Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011, background): “There is a hierarchy for risk of weight gain with AP that has been confirmed in different studies and meta-analyses (88,92,100-106).”